Volastra Therapeutics
NEW YORK, NY · Biotechnology · 42 employees
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its por
Funding history
- Venture - Series Unknown — $30.1M — Sep 2025
- Venture - Series Unknown — $15.0M — May 2024
- Venture - Series Unknown — $60.2M — Mar 2023
Recent signals
- Jan 07, 2026: Volastra Therapeutics Appoints Timothy Bowler as Chief Medical Officer
- Sep 23, 2025: Raised $30.1M in Venture - Series Unknown
- May 27, 2025: Volastra Therapeutics Appoints David P. Southwell as Chief Executive Officer
- Oct 16, 2024: Volastra Therapeutics Appoints Samuel Bakhoum, M.D., Ph.D. as Chief Scientific Officer (CSO)
- May 30, 2024: Raised $15.0M in Venture - Series Unknown
- Mar 13, 2023: Raised $60.2M in Venture - Series Unknown
See plans & pricing → Track Volastra Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.